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Objective: To assess the efficacy and safety of adding liraglutide to established insulin therapy in poorly controlled
Chinese subjects with type 2 diabetes and abdominal obesity compared with increasing insulin dose.
Methods: A 12-week, randomized, parallel-group study was carried out. A total of 84 patients completed the trial
who had been randomly assigned to either the liraglutide-added group or the insulin-increasing group while
continuing current insulin based treatment. Insulin dose was reduced by 0-30% upon the initiation of liraglutide.
Insulin doses were subsequently adjusted to optimized glycemic control. Glycosylated hemoglobin (HbA1c) values,
blood glucose, total daily insulin dose, body weight, waist circumference, and the number of hypoglycemic events
and adverse events were evaluated.
Results: At the end of study, the mean reduction in HbA1c between the liraglutide-added group and the
insulin-increasing group was not significantly different (1.9% vs. 1.77%, p>0.05). However, the percentage of subjects
reaching the composite endpoint of HbA1c ≤ 7.0% with no weight gain and no hypoglycemia, was significantly
higher in the liraglutide-added group than in the insulin-increasing group (67% vs. 19%, p<0.001). Add-on
liraglutide treatment significantly reduced mean body weight (5.62 kg, p<0.01), waist circumference (5.70 cm,
p<0.01), body mass index (BMI) (1.93 kg/m2, p<0.01) and daily total insulin dose (dropped by 66%) during 12-week
treatment period, while all of these significantly increased with insulin increasing treatment. Add-on liraglutide
treated patients had lower rate of hypoglycemic events and greater insulin and oral antidiabetic drugs
discontinuation. Gastrointestinal disorders were the most common adverse events in the liraglutide added
treatment, but were transient.
Conclusions: Addition of liraglutide to abdominally obese, insulin-treated patients led to improvement in glycemic
control similar to that achieved by increasing insulin dosage, but with a lower daily dose of insulin and fewer
hypoglycemic events. Adding liraglutide to insulin also induced a significant reduction in body weight and waist
circumference. Liraglutide combined with insulin may be the best treatment option for poorly controlled type 2
diabetes and abdominal obesity.
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The prevalence of obesity and diabetes has rapidly
increased worldwide Western and Asian countries [1,2].
The association between type 2 diabetes (T2D) and
overweight/obesity is indisputable. In China, the preva-
lence of overweight has increased nearly 50% in a 10-y
period [3]. Obesity, especially visceral fat adiposity, also
increases the risk of T2D, hypertension and atheroscler-
osis, suggesting that obese patients with T2D are at high
risk for cardiovascular disease (CVD) [4]. In addition,
Chinese have more risk factors for CVD because they
have relatively more visceral fat at the same body mass
index (BMI) than Europeans do [5].
Obese patients with T2D ultimately require insulin
therapy to achieve glycemic control over time. How-
ever, insulin treatment is commonly associated with
hypoglycemia and weight gain. Moreover, 70% of insulin-
induced weight gain is fat mass, which in turn worsens
insulin resistance. This then leads to further increases in
insulin requirement and weight gain. A meta-analysis of
waist circumference as predictor of cardiovascular events
has shown that a waist circumference increase of 1 cm
may be associated with a 2% risk increase in cardiovascu-
lar events [6]. In this sense, it is necessary to develop ef-
fective and efficient therapeutic strategy for T2D and
abdominal obesity as well as decreasing cardiovascular
risk.
Glucagon-like peptide-1 (GLP-1) receptor agonists are
the newest class of T2D therapy currently available,
which improve hyperglycemia through increasing insulin
secretion and reducing glucagon secretion [7,8], slowing
gastric emptying, delaying carbohydrate absorption, and
increasing satiety, leading to reduced caloric intake [9].
In Liraglutide Effect and Action in Diabetes (LEAD) 1–6
trials, substantial and sustained improvement in HbA1c,
fasting plasma glucose and postprandial glucose have
been observed with liraglutide treatment [10-15]. Several
studies have shown that liraglutide treatment results in
greater reduction in fat mass than in the lean body mass.
Furthermore, visceral fat mass decreases more than ab-
dominal subcutaneous fat mass [11,12,16]. Therefore lir-
aglutide might be a promising new agent for the
treatment of T2D and abdominal obesity linked to high
risk of CVD.
The combination of exenatide with insulin has been
shown to have an insulin-sparing effect in insulin-
treated patients with T2D as well as a weight loss benefit
in several small uncontrolled studies, furthermore, these
studies reported a low incidence of severe hypoglycemia
[17]. However, only one small retrospective study had
shown that adding liraglutide to insulin therapy resulted
in a significant improvement in glycemic control, reduc-
tion in insulin requirement, and reduction of body
weight without significant hypoglycemia [18]. Therefore,the present study compared the efficacy and safety of
adding liraglutide versus increasing insulin dose strategy




This study was undertaken in the out-patient setting of
the Metabolic Disease Hospital of Tianjin Medical Uni-
versity between October 2011 and May 2012. Patients
eligible for the study met the following criteria: diagnosis
of T2D defined by America Diabetes Association in
2003; HbA1c 7.5~11%; BMI ≥ 25 kg/m2, waist circum-
ference (male ≥ 90 cm and female ≥ 85 cm). The eligible
patients also had to have received insulin injections for
at least 3 months at a dose of at least 10 U/day. Through
reviewing previous medical history, we excluded those
with type 1 diabetes, gestational diabetes or diabetes
with identification secondary causes, significant renal
impairment (estimated creatinine clearance <50 ml/min)
or elevated (≥ 100) alanine or aspartate aminotransferase
(ALT or AST) or congestive heart failure (NYHA Class
III or IV). Patients who were taking medications, aside
from antidiabetic medications, known to affect glycemic
or weight control, such as glucocorticoids or orlistat,
were also excluded.
Study design
This was a parallel-group, open-label, randomized clin-
ical trial over a 12-week observation period. All patients
provided written informed consent and confirmed their
willingness to perform glucose self-monitoring. This
study design was approved by the local ethics committee
review board and was conducted using Good Clinical
Practice in accordance with the Declaration of Helsinki.
The eligible patients were randomized to either the
liraglutide-added group or the insulin-increasing group
on the basis of computer-generated random numbers,
by a person not involved in recruitment of patients. The
withdrawal rate was assumed to be 10%. The glycemic
control target was defined as fasting blood glucose
(FBG) ≤6.1 mmol/L and 2 hour postprandial blood glu-
cose (P2BG) ≤8 mmol/L. In the liraglutide-added group,
liraglutide was initiated at a dose of 0.6 mg injected sub-
cutaneously once per day and increased to 1.2 mg/day
after 1 week. Insulin doses were reduced 0~30% upon
initiation of liraglutide based upon the prescribing diabe-
tologists’ judgement. In the insulin-increasing group, in-
sulin doses were increased to reach the glycemic targets.
During the study, patients continued their usual diet and
exercise regimens as well as any concomitant glucose-
lowering medications. The dialectologists optimized lira-
glutide, insulin dose and antidiabetic agents regimen
according to their judgment based on each patient’s








Age (years) 51.2 ± 10.5 52.7 ± 10.8 NS
Sex (M/F) 26/16 24/18 NS
Duration of diabetes (years) 9.1 ± 3.6 8.9± 3.6 NS
Body weight (kg) 88.6 ± 11.8 86.3 ± 10.3 NS
BMI (kg/m2) 30.4 ± 3.2 30.3 ± 3.0 NS
Waist Circumference (cm) 105.6 ± 12.6 104.6 ± 10.5 NS
Systolic blood pressure (mmHg)
FBG (mmol/L) 8.36 ± 0.93 8.41 ± 0.86 NS
P2BG (mmol/L) 13.76 ± 1.92 13.80 ± 1.96 NS
HbA1c (%) 8.79 ± 0.86 8.69 ± 0.91 NS
Oral antidiabetic agents
Sulfonylurea 7 (16.7%) 9 (21.4%) NS
Thiazolidinedione 17 (40.5%) 14 (33.3%) NS
α-glucosidase inhibitors 15 (35.7) 13 (31.0%) NS
Glinides 16 (38.1%) 13 (31.0%) NS
Metformin 25 (59.5%) 27 (64.3%) NS
Insulin regimen
Total daily insulin dose (units/day) 41.2 ± 17.4 41.6 ± 16.5 NS
Insulin glargine only 11 (26.2%) 13 (31.0%) NS
Insulin NPH only 18 (42.9%) 14 (33.3%) NS
Premixed insulin 13 (31.0%) 15 (35.7%) NS
Data are expressed as mean ± S.D. or frequency [n (%)], BMI: body mass index;
FBG: fasting blood glucose; P2BG: 2-hour postprandial blood glucose; HbA1c:
glycosylated haemoglobin A1c; NS: not significant.
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dialectologists can first decide to discontinue oral insulin
secretagogues in the events of hypoglycemia or
hypoglycemic symptoms occurred in the daytime; if
hypoglycemia occurred in the nighttime, the investiga-
tors can consider decreasing insulin dose or discontinu-
ing insulin treatment according to their clinical
judgements. So this study treatment reflects the real-
world practice. Patients were seen in follow up at base-
line, 2, 4, 8 and 12 weeks.
Clinical measurements
Clinical parameters evaluated at baseline and at 3 months
included HbA1c, total daily insulin dose, total-
triglyceride (TG), total-cholesterol, LDL-cholesterol and
HDL-cholesterol. Body weight, waist circumference,
FBG and P2BG were measured at every clinic visit (base-
line, at 2, 4, 8 and 12 weeks). Hypoglycemic episodes
and adverse events (AEs) were recorded throughout the
study. All patients were taught how to recognize the
signs and symptoms of hypoglycemia and instructed to
obtain a blood glucose reading whenever symptoms of
hypoglycemia occurred. Hypoglycemia was determined by
the number of plasma glucose readings that were below
3.9 mmol/L, or occurrences of definite hypoglycemic
symptoms. Hypoglycemia was considered severe when
the event required third party assistance. Adverse events
were classified as serious if they resulted in death, life-
threatening experiences, hospitalization, or persistent of
significant disability or incapacity.
Statistical analysis
All data are presented as the mean and standard devi-
ation or n and %, and were analysed using SPSS win-
dows version 18.0. Changes in parameters from the
baseline values within group were evaluated using 2-
tailed paired t-test. Unpaired t test was used to compare
the differences in clinical characteristics between groups
at baseline and after treatment assessed for significance
using for the discrete or continuous data and the chi-
square test for frequency distributions. P value <0.05
was considered to be statistically significant.
Results
Baseline clinical characteristics
A total of 90 patients entered the trial and 84 patients
(93.3%) completed the trial. Three patients dropped out
the study (two changed hospital, one was lost of follow
up), three patients were excluded as a result of protocol
violation. Of these, 42 patients were randomly assigned
to receive liraglutide to current insulin therapy (Liraglu-
tide-added group) and 42 patients were assigned to in-
crease the current insulin dose (Insulin-increasing
group). Table 1 shows the demographic and baselinemetabolic characteristics of the randomized population.
At the beginning of the study, the two groups did not
differ regarding anthropometric data, duration of dia-
betes, body weight, BMI, waist circumference, HbA1c,
FBG, P2BG and total daily insulin dose. A similar pro-
portion of patients in the two groups were using insulin
glargine only (26.2% and 31.0%), NPH only (42.9% and
33.3%) and premixed insulin (31.0% and 35.7%) and type
of oral antidiabetic drugs (OAD).
Glycemic control and reduction of diabetes treatment
Over the 12-week treatment period, mean values of
HbA1c, FBG and P2BG were significantly reduced in
both treatment groups. There was no between-group
difference in reduction in FBG and HbA1c. The reduc-
tion in P2BG was larger in the liraglutide-added group
than in the insulin-increasing group (p=0.021) (Table 2).
The mean required total daily insulin dose was signifi-
cantly reduced by 66% from 41.2 ± 17.4 U/day at base-
line to 14.0 ± 12.5 U/day at the end of study in the
liraglutide-added group (p<0.001). In contrast, the mean
required total daily insulin dose was significantly
Table 2 Changes of variables related with glucose metabolism after 12 weeks
Baseline (mean±s.d.) 12 weeks (mean±s.d.) Mean changes from baseline
(95% CI)
★Difference in mean change
(95% CI)
HbA1c (%)
Liraglutide added 8.79 ± 0.86 6.88 ± 0.64 -1.9 (-2.10, -1.72) ** -0.14 (-0.41, 0.13)
Insulin increaing 8.69 ± 0.91 6.93 ± 0.63 -1.77 (-2.00, -1.56) **
PBG (mmol/L)
Liraglutide added 8.36 ± 0.93 6.79 ± 0.48 -1.56 (-1.80, -1.33) ** 0.13 (0.15, -0.16)
Insulin increasing 8.41 ± 0.86 6.72 ± 0.46 -1.69 (-1.90, -1.48) **
P2BG (mmol/L)
Liraglutide added 13.76 ± 1.92 8.39 ± 1.17 -5.40 (-5.8, -4.92) ** -0.83 (-1.59, -0.07) #
Insulin increasing 13.80 ± 1.96 9.26 ± 1.19 -4.54 (-5.0, -4.0) **
Body weight (kg)
Liraglutide added 88.6 ± 11.8 82.9 ± 11.2 -5.62 (-6.51, -4.73) ** -7.6 (-8.67, -6. 57) ##
Insulin increasing 86.3 ± 10.3 88.3 ± 10.4 2.00 (1.52, 2.48) **
BMI (kg/m2)
Liraglutide added 30.4 ± 3.21 28.4 ± 3.04 -1.93 (-2.24, -1.63) ** -2.63 (-2.99, -2.67) ##
Insulin increasing 30.3 ± 2.98 31.00 ± 2.91 0.70 (0.53, 0.86) **
Waist Circumference (cm)
Liraglutide added 105.6 ± 12.6 99.9 ± 11.8 -5.70 (-6.5, -5.0) ** -7.5 (-8.4, -6.6) ##
Insulin increasing 104.6 ± 10.5 106.3 ± 10.4 1.76 (1.30, 2.23) **
★Difference in mean change calculated as Liraglutide minus Insulin; CI, confidence interval; **p<0.01 for mean change from baseline in liraglutide and insulin;
#p<0.05, ## p<0.01 for the between-treatment difference.
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53.5 ± 16.8 U/day at end of study in the insulin-
increasing group (p<0.001). The mean change of total
daily insulin dose was statistically significant in the two
groups (p<0.001). Moreover, of the 42 patients in the
liraglutide-added group, 16 (38%) came off insulin at the
end of study. Furthermore, as a proportion of treatment
use, add-on liraglutide treated patients had greater dis-
continuation of sulfonylureas (85.7% vs. 22.2%, p<0.05),
Glinides (87.5% vs. 46.2%, p<0.05), α-glucosidase inhibi-
tors (66.7% vs. 23.1%, p<0.05) but not thiazolidinediones
and metformin when compared with insulin increasing
treated patients.
Body weight and waist circumference
Body weight, waist circumference and BMI were signifi-
cantly decreased from baseline to 12 weeks in the
liraglutide-added group, the mean reductions in body
weight, waist circumference and BMI were 5.62 kg,
5.70 cm and 1.93 kg/m2 respectively (Table 2). Of the 42
patients in the liraglutide-added group, 26 (62%)
achieved reduction of more than 5% in body weight. In
contrast, body weight, waist circumference and BMI
were significantly increased from baseline to 12 weeks in
the insulin increasing, the mean increases in body
weight, waist circumference and BMI were 2.00 kg,
1.76 cm and 0.70 kg/m2, respectively (Table 2). Thedifferences of mean change in body weight, waist cir-
cumference and BMI were statistically significant in the
two groups (Figure 1, p<0.001).
HbA1c Target goal
At the end of study, an HbA1c ≤ 7.0% level was achieved
by 62 (73.8%) of all the patients in the two groups. The
percentage of subjects with HbA1c ≤ 7.0% with no
hypoglycemia during 12 weeks treatment was signifi-
cantly greater in the liraglutide-added group (67%) than
in the insulin-increasing group (38%) although the per-
centage of subjects achieving HbA1c ≤ 7.0% in all sub-
jects was not different between 2 groups (Figure 2).
Moreover, 67% of patients in the liraglutide-added group
who achieved the composite endpoint of HbA1c ≤ 7.0%
with no weight gain and no hypoglycemia, this was sig-
nificantly higher than 19% of patients in the insulin-
increasing group.
Hypoglycemia
No severe hypoglycemia was reported in the liraglutide-
added group, while two patients in the insulin-increasing
group reported severe hypoglycemia. The percentage of
patients reporting minor hypoglycemic episodes during
the 12-week treatment period was lower in the
liraglutide-added group than in the insulin-increasing
group (11.9% vs. 31.0%, p=0.033).
Figure 1 Mean change of body weight, waist circumference and BMI in the two groups. *p<0.001 for the between-treatment difference.
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The incidence of adverse events was higher in the
liraglutide-added group than in the insulin-increasing
group (57.1% vs. 33.3%, p=0.028). As expected with
GLP-1 receptor agonists, gastrointestinal adverse events
were most commonly reported in the liraglutide-added
group, including nausea, vomiting, constipation, and
diarrhea. These events were mostly mild-to-moderate in
severity and typically resolved after the first 4–8 weeks.
There were no patients withdrawn from the 12 week
study as a result of medication related adverse events in
the two groups.
Discussion
Compared with increasing the insulin dose therapy, the
present study demonstrated the beneficial effects of add-
ing the long-acting GLP-1 analog liraglutide to estab-
lished insulin therapy, which resulted in a significantFigure 2 Percentage of patients achieving composite endpoint of Hbimprovement in glycemic control, reduction in insulin
requirement, lower incidence of hypoglycemia events
and weight loss in the Chinese patients with poorly con-
trolled T2D and abdominal obesity. Although beneficial
effects of combination use of GLP-1 receptor agonists
(liraglutide or exenatide) and insulin were observed in
previous small studies [17-19], most of these are retro-
spective studies. This study is the first designed study
using the insulin dose-increasing approach as an active
comparator.
The data from all six LEAD trials have been analysed
in pooled meta-analysis which has shown that addition
of liraglutide to existing OAD therapy resulted in mean
HbA1c reductions of approximately 1.4% and mean
HbA1c level of 7.1%, and the proportion of subjects with
HbA1c <7% was 59% at the end of trial [20]. In the
present study, addition of liraglutide to the established
insulin therapy resulted in a significant 1.9% decrease inA1c ≤ 7.0%, no hypoglycemia, no weight gain.
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patients treated with addition liraglutide achieved an
HbA1c ≤ 7.0% level at the end of study. Patients in the
insulin-increasing group experienced similar glucose
control compared with that in the liraglutide-added
group, but when compared with the composite endpoint
including HbA1c ≤ 7.0% with no weight gain and no
hypoglycemia, there is a significant difference between
two groups. The composite endpoint goal was achieved
by 67% of patients in the liraglutide-added group which
was significantly higher than that 19% of patients in the
insulin-increasing group. In this study, we also found
that liraglutide-added treatment improved postprandial
glucose control better than insulin-uptitration. One pos-
sible explanation for this beneficial effect is that liraglu-
tide can suppress glucagon secretion in addition to
increasing the physiological insulin secretion [7,8]. Fur-
thermore, add-on liraglutide treated patients had lower
rate of hypoglycemic events and greater insulin and
OAD discontinuation than did patients treated with
increased insulin doses. This suggests that the addition
of liraglutide to insulin therapy might be a good practice
to attain glucose control.
In the Diabetes Control and Complications Trial, sub-
jects assigned to intensive therapy experienced a three-
fold increased risk of severe hypoglycemic events [21]. A
similar finding was also obtained in the UK Prospective
Diabetes Study [22]. In the present study, no severe
hypoglycemia events were reported in liraglutide-added
group, while two patients in the insulin-increasing group
reported severe hypoglycemia. In addition, the percent-
age of patients reporting minor hypoglycemic episodes
during the 12-week treatment period was significantly
lower in the liraglutide-added group than in the insulin-
increasing group. The finding is consistent with the
previous studies [3,10-13] and highlights a second advan-
tage to the liraglutide adding strategy. The lower risk of
hypoglycemia with liraglutide administration may be
explained by its stimulation of insulin release and gluca-
gon suppression in a glucose-dependent manner [23].
Obese patients with T2D are at high risk for CVD [4].
Given that recent studies have shown an association
between hypoglycemic events and risk cardiovascular
events [24], our study may suggest that adding liraglutide
to insulin is advantageous from a cardiovascular stand-
point owing to its reduced frequency of hypoglycemia
compared to treatment with insulin only. In addition to
a lower risk of hypoglycemia, liraglutide may favorably
affect several CV risk factors, such as blood pressure,
lipid profiles, and body weight [11-17,25]. A recent meta-
analysis of cardiovascular safety by exenatide showed
that patients treated with exenatide twice daily were less
likely to have a CVD event than were treated with other
glucose-lowering therapies [26]. The direct cardiovascularbenefits of adding liraglutide should be verified in pro-
spective clinical trials.
Insulin, the most effective therapeutic agent for lower-
ing the blood glucose, is particularly associated with
weight gain [27,28] and especially causes undesirable
weight gain in an already obese population. Therefore it
increases physicians’ reluctance to intensify treatment
and decreases patient adherence. All OADs for the treat-
ment of T2D are associated with either weight gain or
weight neutrality, except for GLP-1 receptor agonist
class which resulted in weight loss through central appe-
tite suppression, leading to reduced energy intake.
Therefore, the third advantage to the liraglutide adding
strategy was the reduction of body weight. In the present
study, a mean weight reduction of 5.62 kg was observed
in the liraglutide-added group at the end of the study. It
is greater than that observed in any of the preclinical
trials of liraglutide as monotherapy or as add-on therapy
to oral agents [10-13] and the trial performed in Asian
countries [3,29]. As seen in a recent observational study
which combined liraglutide and insulin therapy, the
weight loss seen in our study may be explained by a
combination of reduced caloric intake caused by the
appetite-suppressing effect of liraglutide coupled to
reduced lipogenesis achieved by insulin reduction [18].
Moreover, the mean waist circumference reduction of
5.7 cm was most impressive in the liraglutide-added
group. Visceral fat in particular increases the risk of
CVD, with a recent meta-regresion analysis reporting a
2% increase in the relative of a CVD event for 1-cm in-
crease in waist circumference [6]. Therefore, mean
5.7 cm reduction of waist circumference in the
liraglutide-added group was sufficient to reduce the risk
of cardiovascular events.
Participants who are T2D and abdominal obesity are
likely to develop hypertension, hypercholesterolaemia,
liver disease and eventually CVD. Accordingly these par-
ticipants have a considerably elevated risk of morbidity
and mortality. Unfortunately, traditional treatments for
these patients are associated with weight gain and
hypoglycemia that limit the number of patients reaching
acceptable therapeutic goals. The present study provides
evidence that liraglutide, when given to insulin-treated
obese patients with T2D, results in clinically relevant
beneficial effects on body weight and waist circumfer-
ence reduction, lower risk of hypoglycemia and insulin
dose reduction in addition to improved glycemic
control.
Conclusions
In conclusion, adding liraglutide to insulin therapy pro-
vides a better chance of achieving good glycemic control
with a lower daily insulin dose and fewer hypoglycemic
events compared to increasing insulin dose. This
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weight and waist circumference, suggesting that the
addition liraglutide to insulin treatment in obese patients
with T2D maybe a more effective option than increasing
the insulin dose alone. Larger randomized, prospective
studies are required to define the best practices for com-
bination therapy with insulin and liraglutide and to
evaluate its long-term cardiovascular effects.
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